

AMENDMENTS

In the claims:

Please amend the claims as follows.

Claims 1-199 (Canceled).

200. (Currently amended) An isolated peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said peptide selectively homes to tumor vasculature.

201. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 50 residues.

202. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 40 residues.

203. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 35 residues.

204. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 30 residues.

205. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 25 residues.

206. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 20 residues.

207. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 15 residues.

208. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 12 residues.

209. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 10 residues.

210. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 9 residues.

211. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 8 residues.

212. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 7 residues.

213. (Previously presented) The isolated peptide of claim 200, said peptide having a length of less than 6 residues.

214. (Previously presented) An isolated peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), said peptide having a length of less than 100 residues, wherein said peptide selectively binds collagen.

215. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 50 residues.

216. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 40 residues.

217. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 35 residues.

218. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 30 residues.

219. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 25 residues.

220. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 20 residues.

221. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 15 residues.

222. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 12 residues.

223. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 10 residues.

224. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 9 residues.

225. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 8 residues.

226. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 7 residues.

227. (Previously presented) The isolated peptide of claim 214, said peptide having a length of less than 6 residues.

228. (Previously presented) A conjugate comprising a moiety linked to a homing peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), wherein said homing peptide selectively homes to tumor vasculature.

229. (Previously presented) The conjugate of claim 228, wherein said homing molecule selectively homes to breast tumor vasculature.

230. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 50 residues.

231. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 40 residues.

232. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 35 residues.

233. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 30 residues.

234. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 25 residues.

235. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 20 residues.

236. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 15 residues.

237. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 12 residues.

238. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 10 residues.

239. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 9 residues.

240. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 8 residues.

241. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 7 residues.

242. (Previously presented) The conjugate of claim 228, wherein the peptide portion of said conjugate has a length of less than 6 residues.

243. (Previously presented) The conjugate of claim 228, wherein said moiety is a therapeutic agent.

244. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a cancer chemotherapeutic agent.

245. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a cytotoxic agent.

246. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is an anti-angiogenic agent.

247. (Previously presented) The conjugate of claim 243, wherein said therapeutic agent is a polypeptide.

248. (Withdrawn) The conjugate of claim 243, wherein said therapeutic agent is a nucleic acid molecule.

249. (Withdrawn) The conjugate of claim 243, wherein said therapeutic agent is a small molecule.

250. (Withdrawn) The conjugate of claim 243, which comprises a virus.

251. (Withdrawn) The conjugate of claim 250, wherein said virus is a phage.

252. (Previously presented) The conjugate of claim 228, comprising at least two homing molecules that each selectively homes to tumor vasculature.

253. (Previously presented) The conjugate of claim 252, wherein said at least two homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

254. (Previously presented) The conjugate of claim 228, comprising at least ten homing molecules that each selectively homes to tumor vasculature.

255. (Previously presented) The conjugate of claim 254, wherein said at least ten homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

256. (Previously presented) The conjugate of claim 228, comprising at least 100 homing molecules that each selectively homes to tumor vasculature.

257. (Previously presented) The conjugate of claim 256, wherein said at least 100 homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

258. (Withdrawn) The conjugate of claim 256, which comprises a virus.

259. (Withdrawn) The conjugate of claim 258, wherein said virus is a phage.

260. (Previously presented) A conjugate comprising a moiety linked to a homing peptide comprising the amino acid sequence CREKA (SEQ ID NO:1), wherein said homing peptide selectively binds collagen.

261. (Previously presented) The conjugate of claim 260, wherein said homing molecule selectively binds non-helical collagen.

262. (Previously presented) The conjugate of claim 260, wherein said homing molecule selectively binds collagen IV.

263. (Previously presented) The conjugate of claim 262, wherein said homing molecule selectively binds denatured collagen IV in preference to native collagen IV.

264. (Previously presented) The conjugate of claim 262, wherein said homing molecule selectively binds the alpha 2 chain of collagen IV.

265. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 50 residues.

266. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 40 residues.

267. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 35 residues.

268. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 30 residues.

269. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 25 residues.

270. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 20 residues.

271. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 15 residues.

272. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 12 residues.

273. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 10 residues.

274. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 9 residues.

275. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 8 residues.

276. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 7 residues.

277. (Previously presented) The conjugate of claim 260, wherein the peptide portion of said conjugate has a length of less than 6 residues.

278. (Previously presented) The conjugate of claim 260, wherein said moiety is a therapeutic agent.

279. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a cancer chemotherapeutic agent.

280. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a cytotoxic agent.

281. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is an anti-angiogenic agent.

282. (Previously presented) The conjugate of claim 278, wherein said therapeutic agent is a polypeptide.

283. (Withdrawn) The conjugate of claim 278, wherein said therapeutic agent is a nucleic acid molecule.

284. (Withdrawn) The conjugate of claim 278, wherein said therapeutic agent is a small molecule.

285. (Withdrawn) The conjugate of claim 278, which comprises a virus.

286. (Withdrawn) The conjugate of claim 285, wherein said virus is a phage.

287. (Previously presented) The conjugate of claim 260, comprising at least two homing molecules that each selectively binds collagen.

288 (Previously presented) The conjugate of claim 287, wherein said at least two homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

289. (Previously presented) The conjugate of claim 260, comprising at least ten homing molecules that each selectively binds collagen.

290. (Previously presented) The conjugate of claim 289, wherein said at least ten homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).

291. (Previously presented) The conjugate of claim 260, comprising at least 100 homing molecules that each selectively binds collagen.

292. (Previously presented) The conjugate of claim 291, wherein said at least 100 homing molecules each independently comprises the amino acid sequence CREKA (SEQ ID NO: 1).



293. (Withdrawn) The conjugate of claim 291, which comprises a virus.
294. (Withdrawn) The conjugate of claim 293, wherein said virus is a phage.
295. (Withdrawn) A fusion protein comprising the amino acid sequence CREKA (SEQ ID NO: 1) fused to a heterologous protein.
296. (Withdrawn) A bifunctional peptide comprising the amino acid sequence CREKA (SEQ ID NO: 1) fused to a heterologous peptide.
297. (Withdrawn) The bifunctional peptide of claim 296, further comprising the peptide<sub>D</sub>(KLAKLAK).
298. (Withdrawn) The bifunctional peptide of claim 297, wherein said bifunctional peptide is CREKA-GG-<sub>D</sub>(KLAKLAK)<sub>2</sub>.